Objectives: Opioid receptors mediate the cardioprotection of remote ischemic preconditioning (RIPC). The authors tested the hypothesis that morphine reduces the threshold of cardioprotection produced by RIPC.
P
RZYKLENK ET AL 1 found that brief episodes of ischemia in one coronary bed render remote virgin myocardium resistant to infarction; this phenomenon was named "remote ischemic preconditioning (RIPC)." Subsequent studies confirmed the existence of this protective effect of remote preconditioning in other organs, such as the kidney, 2 small intestine, 3 or skeletal muscle. 4 Although the mechanisms of RIPC are incompletely understood, some similarities to ischemic preconditioning have been discovered in the conveyance of external signals to intracellular targets that ultimately lead to protection. 5 RIPC also can be elicited via opioids, bradykinin, and adenosine, which are released from the remote organ during the preconditioning ischemia and carried to the heart in the bloodstream. 5 It was shown that ␦1-and -opioid receptors are mediated in the cardioprotection of RIPC. 6, 7 Morphine, a -receptor agonist with ␦-and -receptor agonist properties, 8 has been shown to mimic ischemic preconditioning in the intact and isolated rat hearts. 9, 10 Previous studies indicated that morphine enhances the cardioprotection induced by isoflurane or helium preconditioning. 11-13 The addition of morphine infusion to RIPC during reperfusion could confer a greater percentage of ST-segment resolution and lower peak troponin I levels in patients subjected to primary percutaneous coronary intervention. 14 In this study, the authors hypothesized that morphine reduces the threshold of cardioprotection induced by RIPC. The authors further hypothesized that this protective effect is mediated by the activation of opioid receptors in rats.
METHODS
This study was conducted in accordance with the institutional guidelines on the use of live animals for research, and the experimental protocol was approved by the Animal Care and Use Committee of Anhui Medical University, Hefei, China. Male Sprague-Dawley rats weighing between 280 and 300 g were used for this study. Rats were anesthetized by the intraperitoneal administration of pentobarbitone (50 mg/kg) and maintained by repeat doses of 25 mg/kg every 60 to 90 minutes as necessary. All the animals underwent tracheotomy and tracheal intubation. Mechanical ventilation was provided with a Harvard Apparatus Rodent Respirator (Harvard Apparatus, Boston, MA), and the rats were ventilated with room air at 70 to 80 breaths/min. Their body temperature was monitored and maintained at 37°Ϯ 1°C (mean Ϯ standard deviation) using a heating pad. The right carotid artery was cannulated for direct blood pressure monitoring via a pressure transducer and a lead-II electrocardiogram-monitored heart rate via subcutaneous stainless steel electrodes connected to a PowerLab monitoring system (ML750 PowerLab/4sp with MLT0380 Reusable BP Transducer; AD Instruments, Colorado Springs, CO). Hemodynamic values, including heart rate and mean arterial blood pressure (MAP), were recorded at baseline, at the end of the treatment period, and at the end of the ischemia and reperfusion periods for comparison. The left femoral vein was cannulated for drug administration. A left thoracotomy was performed to expose the heart at the 5th intercostal space. After removing the pericardium, a 6-0 Prolene loop along with a snare occluder were placed at the origin of the left coronary artery in preparation for inducing ischemia-reperfusion injury. Regional ischemia was induced by pulling the snare and securing the threads with a mosquito hemostat. Ischemia was confirmed by electrocardiographic changes, a substantial decrease in MAP, and cardiac cyanosis. Rats were omitted from further data analysis if severe hypotension (arterial mean blood pressure Ͻ30 mmHg) or intractable ventricular fibrillation occurred. After surgical preparation, the rat was allowed to stabilize for 15 minutes.
Rats were assigned randomly to receive 1 of 7 treatments (Fig 1) . All animals were subjected to 30 minutes of ischemia by occlusion of the left coronary artery followed by 2 hours of reperfusion by release of the occlusion; the RIPC1 and RIPC3 groups were, respectively, induced by 1 or 3 cycles of 5 minutes of right femoral artery ischemia induced by an atraumatic vessel clip interspersed with 5 minutes of reperfusion before coronary occlusion. A nonspecific opioid-receptor antagonist naloxone (NAL) was used to evaluate the involvement of opioid receptors. The intravenous morphine (MOR) and NAL groups were, respectively, induced by MOR (0.1 mg/kg 13 ) or NAL (6 mg/kg 13 ) administered 30 minutes before sustaining ischemia. MOR ϩ RIPC1 and NAL ϩ MOR ϩ RIPC1 groups of rats received 1 cycle of 5 minutes of right femoral artery ischemia interspersed with 5 minutes of reperfusion plus morphine (0.1 mg/kg) in the absence or presence of NAL (6 mg/kg) before ischemia and reperfusion injury. The negative control (CON) group merely underwent ischemia and reperfusion injury.
The hearts were excised and transferred to a Langendorff apparatus on completion of the reperfusion period and immediately perfused with normal saline for 1 minute at a pressure of 100 cmH 2 O to flush out residual blood. The snare was retightened securely, and 0.25% Evan blue dye was injected to stain the normally perfused region of the heart. This procedure allowed visualization of the normal, nonischemia region and the area at risk (AAR). The hearts then were frozen and cut into 2-mm slices. Thereafter, the slices were stained by incubation at 37°C for 20 minutes in 1% 2, 3, 5-triphenyltetrazolium in phosphate buffer at a pH of 7.4. This was followed by immersion in 10% formalin for 20 minutes to enhance the contrast of the stain. The areas of infarct and risk zone for each slice were traced and digitized using a computerized planimetry technique (SigmaScan 4.0; SYSTAT Software, Inc, Richmond, CA). The infarct size (IS) was expressed as a percentage of the AAR.
Data are expressed as mean Ϯ standard deviation, and data analysis was performed with a personal computer statistical software package (Prism v4.0; GraphPad Software, San Diego, California). The hemodynamic data were analyzed using two-way analysis of variance, with the Bonferroni correction applied for multiple comparisons if significant F ratios were obtained. Risk areas and infarct sizes, expressed as a percentage of the area at risk (IS/AAR), were analyzed among groups using 1 way analysis of variance with a Student-Newman-Keuls post hoc test for multiple comparisons. Statistical differences were considered significant if the p-value was less than 0.05.
RESULTS
A total of 45 rats were instrumented to obtain 42 rats in the study. Three rats were omitted from further data analysis for severe hypotension or intractable ventricular fibrillation. There was 1 each from those receiving RIPC3, NAL, and MOR ϩ RIPC1 treatments.
Hemodynamic values including heart rate, mean arterial blood pressure, and the rate-pressure product (RPP) at baseline, after treatment, 30 minutes after left coronary artery occlusion, and after 2 hours of reperfusion were collected (Table 1 ). There were no significant differences among groups at baseline, after treatment, at 30 minutes of occlusion, and at 2 hours of reperfusion. Compared with baseline, MAP and RPP were reduced only after MOR ϩ RIPC1 treatment. During ischemia and reperfusion, MAP and RPP declined 23% to 39% and 34% to 44%, respectively, from baseline (p Ͻ 0.05 and p Ͻ 0.01 v baseline), confirming the successful induction of ischemia and reperfusion injury model.
The AAR ranged from 0.41 Ϯ 0.04 cm 3 to 0.46 Ϯ 0.06 cm 3 , and there was no difference in AAR between the control and treatment groups. As shown in Figure 2 , the IS/AAR of the CON group was 54.7% Ϯ 6.0%; RIPC3 and MOR ϩ RIPC1 markedly reduced IS/AAR to 28.3% Ϯ 4.9% and 29.0% Ϯ 7.0%, respectively (p Ͻ 0.01 v CON). RIPC1 and MOR (0.1 mg/kg) or NAL (6 mg/kg) before sustaining ischemia had no effect on infarct size (IS/AAR: RIPC1, 51.1% Ϯ 7.4%; MOR, 53.8% Ϯ 6.7%; NAL, 54.4% Ϯ 6.9%; p Ͼ 0.05 v control). However, NAL could reverse the cardioprotective effect produced by MOR ϩ RIPC1 treatment (IS/AAR: NAL ϩ MOR ϩ RIPC1, 55.2% Ϯ 6.5%; p Ͻ 0.01 v MOR ϩ RIPC1).
DISCUSSION
The results from this study confirmed previous findings 7 showing that 3 cycles of 5 minutes each of femoral artery ischemia interspersed with 5 minutes of reperfusion before coronary occlusion produced a protective effect against myocardial ischemia and reperfusion injury. Then, 1 cycle of 5 minutes of femoral artery ischemia interspersed with 5 minutes of reperfusion or pretreament with MOR (0.1 mg/kg) without ischemia before sustaining ischemia could not show this protection. However, the combination of this low dose of MOR and a single 5-minute cycle of femoral artery ischemia and reperfusion reduced the myocardial infarct size to a similar extent to 3 cycles of femoral artery ischemia and reperfusion, indicating that morphine reduces the threshold of RIPC. NAL abolished the protective effect induced by the combination of subthreshold doses of MOR and RIPC, implying that opioid receptors mediate this additive effect. It is interesting to note that the combination of morphine and RIPC1 reduced the RPP, suggesting a better recovery of myocardial function.
Opioid-receptor agonists, including morphine, 9,10 fentanyl, 15 and remifentanil, 16 were shown to induce cardioprotection when administered before and after prolonged ischemia. Pretreatment with morphine at a dose of 0.3 mg/kg before ischemia reduced the myocardial infarct size. 12 Patel et al 17 found that NAL, the nonspecific opioid-receptor antagonist, was capable of canceling the myocardial infarct-limiting effects produced by remote intestinal preconditioning in rats. They showed the involvement of opioid signaling in RIPC. Dickson et al 18 revealed that the administration of a reverse-phase concentrate generated from the coronary effluent of preconditioned rabbit hearts evokes significant protection in mesenteric tissue, which is mediated by opioid-receptor stimulation and K ATP channel activation. Subsequent experimental studies have shown the role of the ␦1-opioid receptor in remote limb preconditioning of skeletal muscle in pigs and in remote infrarenal aortic preconditioning of rat hearts. 4, 6 Nevertheless, Zhang et al 7 failed to detect the involvement of the ␦1-opioid receptor and instead showed the -opioid receptor in remote preconditioning by a femoral artery ischemia stimulus to reduce the myocardial infarct size in rat hearts. It has been documented that endogenous opioids generated by the preconditioning stimulus in the remote organ or tissue enter the bloodstream where they act directly on the myocardium to produce cardioprotective effects.
Ludwig et al 12 indicated that the combined administration of MOR and isoflurane produces a significant reduction in myocardial infarct size that greatly exceeds the protection induced by either drug alone in rats. The investigation also showed that MOR lowers the threshold of helium preconditioning and also implied that opioid receptors mediate helium preconditioning and its augmentation by MOR in rabbits. 13 A single-center, parallel-group, randomized study showed that when applying RIPC induced by 3 cycles of 4 minutes each inflating a blood pressure cuff placed on the upper limb interspersed with 4 minutes of deflating the cuff, both alone and in combination with intravenous infusion of morphine just before and at the onset or reperfusion to acute ST-segment elevation myocardial infarction patients, a higher proportion of full resolution of ST-segment deviation 30 minutes after primary percutaneous coronary intervention was achieved. However, the addition of morphine infusion to RIPC did not confer an improvement as far as the primary efficacy measure (full ST-segment resolution) was concerned, but it was associated with a greater percentage of ST-segment resolution and lower peak troponin I levels. 14 There are several limitations to this study. First, the results obtained were restricted to rats; there may be relevant species differences in the severity and duration of the ischemia response and its modulation by these treatments. Second, as observed in the current investigation, remote ischemic preconditioning previously was shown to be dependent on the number of brief exposure episodes induced before left coronary artery ischemia and reperfusion. Whether exposure episodes shorter than 5 minutes also will reduce myocardial infarct size in rats was not examined in this study and remains to be shown. Third, whether morphine could enhance the cardioprotective effects conferred by 3 cycles of RIPC also was not studied. Finally, the study design did not allow conclusion of the specific opioid receptor of the observed effect.
In summary, these findings have shown that remote preconditioning by femoral artery occlusion before sustaining ischemia produces protective effects against myocardial ischemia and reperfusion injury in rats. It was further shown that mophine reduces the threshold of the remote ischemic preconditioning and also indicates that opioid receptors mediate this augmentative effects. These findings are strongly suggestive of a potentially useful role of remote ischemic preconditioning and morphine administration for the prevention of ischemia and reperfusion injury during cardiopulmonary bypass in patients.
